Details for 2022744149
Up to date per 04.04.2026
Actions
Details for 2022744149
Granted/Registered
European Patent
08.05.2024 A
10.09.2025 B1
02.07.2021
US
202163217970 P
C07D 237/34 20060101AFI20230106BHEP
Owner
Astrazeneca AB 151 85 SödertäljeSE
Mitsubishi Tanabe Pharma Corporation3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505JP
Representative
Authorized Recipients
Paul CosmoviciGumpendorfer Straße 1421060 WienAT
Paul CosmoviciGumpendorfer Straße 1421060 WienAT
Inventor
JOHANSSON, Lars Anders Mikael 151 SödertäljeSE
GRADÉN, Henrik 151 SödertäljeSE
BERGONZINI, Giulia 151 SödertäljeSE
SUGAMA, Hiroshi Osaka-shi, Osaka 541-8505JP
MATSUMURA, Takehiko Osaka-shi, Osaka 541-8505JP
Information about Fees